Nevirapine & AZT

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: Nevirapine & AZT
• 英文别名: 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione;2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
• 化学式: C25H27N9O5
• 分子量: 533.5
• InChiKey: WLSLPVFXRKZOPR-XKPASDJRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.45
• 重原子数：
  39
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  151
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• [EN] CRYSTALLINE FORMS OF (2R,5S,13AR)-8-HYDROXY-7,9-DIOXO-N-(2,4,6-TRIFLUOROBENZYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO [1',2':4,5] PYRAZINO [2,1-B] [1,3] OXAZEPINE-10-CARBOXAMIDE<br/>[FR] FORMES CRISTALLINES DE (2R,5S,13AR)-8-HYDROXY-7,9-DIOXO-N-(2,4,6-TRIFLUOROBENZYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-MÉTHANPYRIDO[1',2':4,5]PYRAZINO 2,1-B][1,3]OXAZÉPINE-10-CARBOXAMIDE
  申请人：GILEAD SCIENCES INC

  公开号：WO2015196137A1

  公开（公告）日：2015-12-23

  The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanpyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2 R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.

  本发明涉及(2R,5S,13aR)-8-羟基-7,9-二氧-N-(2,4,6-三氟苯基甲基)-2,3,4,5,7,9,13,13a-八氢-2,5-甲基吡啶[1',2':4,5]吡嗪[2,1-b][1,3]噁唑-10-羧酰胺的晶体形式和共晶体，以及其制药配方和治疗用途。本发明还涉及新的晶体形式的钠(2R,5S,13aR)-7,9-二氧-10-((2,4,6-三氟苯基甲基)氨基)-2,3,4,5,7,9,13,13a-八氢-2,5-甲基吡啶[1',2':4,5]吡嗪[2,1-b][1,3]噁唑-8-olate Form I。
• CRYSTALLINE FORMS OF (2R,5S,13AR)-8-HYDROXY-7,9-DIOXO-N-(2,4,6-TRIFLUOROBENZYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO [1',2':4,5]PYRAZINO [2,1-B][1,3]OXAZEPINE-10-CARBOXAMIDE
  申请人：Gilead Sciences, Inc.

  公开号：EP3157931A1

  公开（公告）日：2017-04-26